Dimethyltryptamine

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging ClinicsTM as the new brand name and visual identity for its planned U.S. network of brain PET scanning centers being launched at the HCA Florida University Medical Offices building in Davie, and featuring the U.S. FDA-cleared CareMiBrain™ system, a groundbreaking, standalone PET scanner without an integrated CT component. NovaScan Neuroimaging ClinicsTM The new brand name and visual identity has been designed with a clean and elegant look reflective of the Company’s vision for a streamlined approach to dedicated brain PET imaging, and the revolutionary technology that the Company clinics will feature. The name incorporates the words “Nova” and “Scan”, the former of which is a Latin derivative meaning ‘new’. Together, they combine to form an original name capturing the spirit of the next chapter in medical imaging to be anchored in optimized scanning, highest quality reporting, rapid turnarounds, and a high-touch, comfort enhanced patient experience. The navy and red fonts offer a strong element of American heritage while the logo, comprised of an offset collection of two groupings of circles has been designed to reflect the shape of a brain and its stem. The circles represent the aspiration of cognitive health and harmony for all patients while the various colors – blue, purple, green, pink, and grey – evoke additional sentiments of trust, insight, renewal, compassion, and balance in the delivery of our medical services. The Florida clinic will be the first of its kind in the U.S. providing dedicated, brain optimized PET scans to aid in the detection and treatment of Alzheimer’s Disease, by confirming the presence of beta-amyloid plaques associated with Alzheimer’s progression. The clinic will also scan patients for other forms of dementia, epilepsy, Parkinson’s disease, multiple sclerosis, and brain cancer, and will also be available for use in clinical trials to help test new tracers being developed. Because The CareMiBrain™ technology is a standalone system and is not combined with computed tomography (CT), patients receive 25% less radiation. With traditional PET/CT scanners, the CT component cannot be turned off during a brain scan because the data and images are interwoven. “Our goal was to settle on a name and symbol that would capture the essence of what we are planning to achieve in offering a new approach to dedicated brain PET scanning as an important component of the healthcare system,” says Christopher J. Moreau, CEO of Algernon Health. “We will quite literally be offering a ‘new scan’ and experience through our clinics and an advanced standard of technology and service to patients and the medical community alike.” The Company’s inaugural clinic at the HCA Florida University Medical Offices building in Davie, is approximately twenty minutes southwest of Fort Lauderdale. Click here for a 3D tour of the very first NovaScan Neuroimaging ClinicsTM location in the U.S., to be opened in a newly built suite, which is currently being furnished and fully outfitted: Offices 360 View HCA Florida University Medical Office Building - Davie, Florida. Algernon will provide an update shortly on its planned official clinic opening date and when it will be able to start accepting referrals and begin conducting PET brain scans for patients. Christopher J. Moreau CEO Algernon Health Inc. 604.398.4175 Ext 701 cjmoreau@algernonhealth.com https://www.algernonhealth.com/ About Algernon Health Algernon is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease, and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson’s disease. Algernon has a program for Repirinast, a repurposed drug for CKD, and is also the parent company of Algernon NeuroScience, a wholly owned subsidiary, that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company’s chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold for USD $2M cash and a 20% equity position in Seyltx, a private U.S. based drug development company that continues to advance research on the drug. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to clinic opening, both the inaugural site and additional clinic locations throughout the U.S., referral acceptance and the offering of PET scanning timelines, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2afd6e51-0b3f-44d0-9991-2605ad1127b5 https://www.globenewswire.com/NewsRoom/AttachmentNg/c8a9435c-52c8-4b36-be88-3b934eab64ba https://www.globenewswire.com/NewsRoom/AttachmentNg/7c3779f2-f9da-4682-bec1-e43def72e022 Released March 25, 2026

Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fundExpands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500®Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting AtaiBeckley’s enhanced eligibility following its U.S. re-domiciliation and building on its addition to the Nasdaq Biotechnology Index in December 2025 NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: "Being added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S. benchmark indices reflects meaningful recognition of AtaiBeckley's enhanced presence in U.S. equity markets, with the CRSP index alone tracking more than $3 trillion in passively managed assets. These inclusions broaden our reach across index-tracking strategies and build on our earlier addition to the Nasdaq Biotechnology Index in December 2025. We see these additions as a natural progression as AtaiBeckley’s market profile grows alongside our advancing clinical pipeline, including BPL-003’s anticipated Phase 3 initiation in the second quarter." The S&P Total Market Index tracks virtually all U.S.-listed common stocks traded on the NYSE, NYSE American, NASDAQ National Market, and NASDAQ Small Cap exchanges, providing comprehensive coverage of the investable U.S. equity universe. The S&P Completion Index comprises all members of the S&P Total Market Index that are not current constituents of the S&P 500®, offering broad exposure to approximately 3,000 mid-, small-, and micro-cap U.S. companies. These indexes are widely used by institutional investors and asset managers as benchmarks for passive investment strategies. The CRSP® benchmark indices are maintained by the Center for Research in Security Prices, formerly a research center of the University of Chicago Booth School of Business and acquired by Morningstar, Inc. in February 2026, and serve as the basis for index funds representing more than $3 trillion in assets, including the world’s largest mutual fund. CRSP indexes are reconstituted quarterly and are routinely adopted by institutional investors, including Vanguard, as the basis for broad-market passive strategies. About AtaiBeckley Inc.AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the expected impact of the inclusion on the indices; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; and the plans and objectives of management for future operations, research and development and capital expenditures. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our quarterly reports and other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.Contact Information:Investors: Jason Awe, PhDVP, Investor RelationsIR@ataibeckley.com Media: Charlotte ChorleyAssociate Director, CommunicationsPR@ataibeckley.com